How are MCPIP1 and cytokines mutually regulated in cancer-related immunity?

Abstract

Cytokines are secreted by various cell types and act as critical mediators in many physiological processes, including immune response and tumor progression. Cytokines production is precisely and timely regulated by multiple mechanisms at different levels, ranging from transcriptional to post-transcriptional and posttranslational processes. Monocyte chemoattractant protein-1 induced protein 1 (MCPIP1), a potent immunosuppressive protein, was first described as a transcription factor in monocytes treated with monocyte chemoattractant protein-1 (MCP-1) and subsequently found to possess intrinsic RNase and deubiquitinase activities. MCPIP1 tightly regulates cytokines expression via various functions. Furthermore, cytokines such as interleukin 1 beta (IL-1B) and MCP-1 and inflammatory cytokines inducer lipopolysaccharide (LPS) strongly induce MCPIP1 expression. Mutually regulated MCPIP1 and cytokines form a complicated network in the tumor environment. In this review, we summarize how MCPIP1 and cytokines reciprocally interact and elucidate the effect of the network formed by these components in cancer-related immunity with aim of exploring potential clinical benefits of their mutual regulation.

Keywords

MCPIP1 / cytokines / cancer-related immunity / RNase / deubiquitinase

References

[1] Algra AM, Rothwell PM (2012) Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 13(5):518–527

[2] Boratyn E, Nowak I, Horwacik I, Durbas M, Mistarz A, Kukla M, Kaczówka P, Łastowska M, Jura J, Rokita H (2016) Monocyte chemoattractant protein-induced protein 1 overexpression modulates transcriptome, including microRNA, in human neuroblastoma cells. J Cell Biochem 117(3):694–707

[3] Brana I, Calles A, LoRusso PM, Yee LK, Puchalski TA, Seetharam S, Zhong B, de Boer CJ, Tabernero J, Calvo E (2015) Carlumab, an anti-CC chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Target Oncol 10(1):111–123

[4] Chitu V, Stanley ER (2006) Colony-stimulating factor-1 in immunity and inflammation. Curr Opin Immunol 18(1):39–48

[5] Coffelt SB, De Visser KE (2014) Cancer: inflammation lights the way to metastasis. Nature 507(7490):48–49

[6] Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30(7):1073–1081

[7] Costinean S, Sandhu SK, Pedersen IM, Tili E, Trotta R, Perrotti D, Ciarlariello D, Neviani P, Harb J, Kauffman LR (2009) Src homology 2 domain–containing inositol-5-phosphatase and CCAAT enhancer-binding protein β are targeted by miR-155 in B cells of Eμ-MiR-155 transgenic mice. Blood JAmSoc Hematol 114(7):1374–1382

[8] Coussens LM, Zitvogel L, Palucka AK (2013) Neutralizing tumorpromoting chronic inflammation: a magic bullet? Science 339 (6117):286–291

[9] Deng L, Wang C, Spencer E, Yang L, Braun A, You J, Slaughter C, Pickart C, Chen ZJ (2000) Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103(2):351–361

[10] Dhamija S, Winzen R, Doerrie A, Behrens G, Kuehne N, Schauerte C, Neumann E, Dittrich-Breiholz O, Kracht M, Holtmann H (2013) Interleukin-17 (IL-17) and IL-1 activate translation of overlapping sets of mRNAs, including that of the negative regulator of inflammation, MCPIP1[J]. J Biol Chem 288(26):19250–19259

[11] Diakos CI, Charles KA, McMillan DC, Clarke SJ (2014) Cancerrelated inflammation and treatment effectiveness. Lancet Oncol 15(11):e493–e503

[12] Dobosz E, Wilamowski M, Lech M, Bugara B, Jura J, Potempa J, Koziel J (2016) MCPIP-1, alias regnase-1, controls epithelial inflammation by posttranscriptional regulation of IL-8 production [J]. J Innate Immun 8(6):564–578

[13] Dysthe M, Parihar R (2020) Myeloid-derived suppressor cells in the tumor microenvironment. In: Tumor microenvironment 2020. Springer, Cham, pp 117–140

[14] Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA (2013) Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 13(11):759

[15] Fiori ME, Di Franco S, Villanova L, Bianca P, Stassi G, De Maria R (2019) Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol Cancer 18(1):70

[16] Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. In: Seminars in oncology. WB Saunders, vol 29(6), pp 15–18

[17] Fu M, Blackshear PJ (2017) RNA-binding proteins in immune regulation: a focus on CCCH zinc finger proteins. Nat Rev Immunol 17(2):130

[18] Galdiero MR, Marone G, Mantovani A (2018) Cancer inflammation and cytokines. Cold Spring Harb Perspect Biol 10(8):a028662

[19] Garderet L, Kuhnowski F, Berge B, Roussel M, Escoffre-Barbe M, Lafon I, Facon T, Leleu X, Karlin L, Perrot A (2018) Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. Blood 132(24):2555–2563

[20] Garg AV, Amatya N, Chen K, Cruz JA, Grover P, Whibley N, Conti HR, Mir GH, Sirakova T, Childs EC (2015) MCPIP1 endoribonuclease activity negatively regulates interleukin-17-mediated signaling and inflammation. Immunity 43(3):475–487

[21] Gierach GL, Lacey JV, Schatzkin A, Leitzmann MF, Richesson D, Hollenbeck AR, Brinton LA (2008) Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health–AARP Diet and Health Study. Breast Cancer Res 10(2):R38

[22] Gordon S, Martinez FO (2010) Alternative activation of macrophages: mechanism and functions. Immunity 32(5):593–604

[23] Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, Cai X, Fox JG, Goldenring JR, Wang TC (2004) Gastric cancer originating from bone marrow-derived cells. Science 306 (5701):1568–1571

[24] Huang S, Miao R, Zhou Z, Wang T, Liu J, Liu G, Chen YE, Xin HB, Zhang J, Fu M (2013) MCPIP1 negatively regulates toll-like receptor 4 signaling and protects mice from LPS-induced septic shock. Cell Signal 25(5):1228–1234

[25] Huang S, Liu S, Fu JJ, Wang TT, Yao X, Kumar A, Liu G, Fu M (2015) Monocyte chemotactic protein-induced protein 1 and 4 form a complex but act independently in regulation of interleukin-6 mRNA degradation. J Biol Chem 290(34):20782–20792

[26] Iwasaki H, Takeuchi O, Teraguchi S, Matsushita K, Uehata T, Kuniyoshi K, Satoh T, Saitoh T, Matsushita M, Standley DM (2011) The IκB kinase complex regulates the stability of cytokineencoding mRNA induced by TLR–IL-1R by controlling degradation of regnase-1. Nat Immunol 12(12):1167

[27] Jeltsch KM, Hu D, Brenner S, Zöller J, Heinz GA, Nagel D, Vogel KU, Rehage N, Warth SC, Edelmann SL (2014) Cleavage of roquin and regnase-1 by the paracaspase MALT1 releases their cooperatively repressed targets to promote T H 17 differentiation. Nat Immunol 15(11):1079

[28] Jiang H, Lv X, Lei X, Yang Y, Yang X, Jiao J (2016) Immune regulator MCPIP1 modulates TET expression during early neocortical development. Stem cell Rep 7(3):439–453

[29] Kapoor N, Niu J, Saad Y, Kumar S, Sirakova T, Becerra E, Li X, Kolattukudy PE (2015) Transcription factors STAT6 and KLF4 implement macrophage polarization via the dual catalytic powers of MCPIP. J Immunol 194(12):6011–6023

[30] Karin M, Greten FR (2005) NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5(10):749–759

[31] Kasza A, Wyrzykowska P, Horwacik I, Tymoszuk P, Mizgalska D, Palmer K, Rokita H, Sharrocks AD, Jura J (2010) Transcription factors Elk-1 and SRF are engaged in IL1-dependent regulation of ZC3H12A expression. BMC Mol Biol 11(1):14

[32] Leggas M, Kuo KL, Robert F, Cloud G, Deshazo M, Zhang R, Li M, Wang H, Davidson S, Rinehart J (2009) Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy. Cancer Chemother Pharmacol 63(4):731–743

[33] Li M, Cao W, Liu H, Zhang W, Liu X, Cai Z, Guo J, Wang X, Hui Z, Zhang H (2012) MCPIP1 down-regulates IL-2 expression through an ARE-independent pathway[J]. PLoS One 7(11): e49841

[34] Liang J, Wang J, Azfer A, Song W, Tromp G, Kolattukudy PE, Fu M (2008) A novel CCCH-zinc finger protein family regulates proinflammatory activation of macrophages. J Biol Chem 283(10):6337–6346

[35] Liang J, Saad Y, Lei T, Wang J, Qi D, Yang Q, Kolattukudy PE, Fu M (2010) MCP-induced protein 1 deubiquitinates TRAF proteins and negatively regulates JNK and NF-κB signaling. J Exp Med 207(13):2959–2973

[36] Lu W, Ning H, Gu L, Peng H, Wang Q, Hou R, Fu M, Hoft DF, Liu J (2016) MCPIP1 selectively destabilizes transcripts associated with an antiapoptotic gene expression program in breast cancer cells that can elicit complete tumor regression. Cancer Res 76(6):1429–1440

[37] Maman S, Witz IP (2018) A history of exploring cancer in context. Nat Rev Drug Discov 17(3):13–30

[38] Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436–444

[39] Marcuzzi E, Angioni R, Molon B, Calì B (2019) Chemokines and chemokine receptors: orchestrating tumor metastasization. Int J Mol Sci 20(1):96

[40] Marona P, Górka J, Mazurek Z, Wilk W, Rys J, Majka M, Jura J, Miekus K (2017) MCPIP1 downregulation in clear cell renal cell carcinoma promotes vascularization and metastatic progression. Cancer Res 77(18):4905–4920

[41] Matsushita K, Takeuchi O, Standley DM, Kumagai Y, Kawagoe T, Miyake T, Satoh T, Kato H, Tsujimura T, Nakamura H (2009) Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. Nature 458(7242):1185–1190

[42] Miao R, Huang S, Zhou Z, Quinn T, Van Treeck B, Nayyar T, Dim D, Jiang Z, Papasian CJ, Eugene Chen Y (2013) Targeted disruption of MCPIP1/Zc3h12a results in fatal inflammatory disease. Immunol Cell Biol 91(5):368–376

[43] Mino T, Murakawa Y, Fukao A, Vandenbon A, Wessels HH, Ori D, Uehata T, Tartey S, Akira S, Suzuki Y (2015) Regnase-1 and roquin regulate a common element in inflammatory mRNAs by spatiotemporally distinct mechanisms. Cell 161(5):1058–1073

[44] Mizgalska D, Węgrzyn P, Murzyn K, Kasza A, Koj A, Jura J, Jarzab B, Jura J (2009) Interleukin-1-inducible MCPIP protein has structural and functional properties of RNase and participates in degradation of IL-1β mRNA. FEBS J 276(24):7386–7399

[45] Monin L, Gudjonsson JE, Childs EE, Amatya N, Xing X, Verma AH, Coleman BM, Garg AV, Killeen M, Mathers A (2017) MCPIP1/regnase-1 restricts IL-17A–and IL-17C–dependent skin inflammation. J Immunol 198(2):767–775

[46] Murray PJ (2017) Macrophage polarization. Annu Rev Physiol 10 (79):541–566

[47] Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T (2014) Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41(1):14–20

[48] Muzio M, Natoli G, Saccani S, Levrero M, Mantovani A (1998) The human Toll signaling pathway: divergence of nuclear factor κB and JNK/SAPK activation upstream of tumor necrosis factor receptor–associated factor 6 (TRAF6). J Exp Med 187(12):2097–2101

[49] Niu J, Azfer A, Zhelyabovska O, Fatma S, Kolattukudy PE (2008) Monocyte chemotactic protein (MCP)-1 promotes angiogenesis via a novel transcription factor, MCP-1-induced protein (MCPIP). J Biol Chem 283(21):14542–14551

[50] Niu J, Shi Y, Xue J, Miao R, Huang S, Wang T, Wu J, Fu M, Wu ZH (2013) USP10 inhibits genotoxic NF-κB activation by MCPIP1-facilitated deubiquitination of NEMO. The EMBO journal. 32(24):3206–3219

[51] O’Boyle G, Brain JG, Kirby JA, Ali S (2007) Chemokine-mediated inflammation: identification of a possible regulatory role for CCR2. Mol Immunol 44(8):1944–1953

[52] Oh YT, Qian G, Deng J, Sun SY (2018) Monocyte chemotactic protein-induced protein-1 enhances DR5 degradation and negatively regulates DR5 activation-induced apoptosis through its deubiquitinase function. Oncogene 37(25):3415–3425

[53] Ono M (2008) Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci 99(8):1501–1506

[54] Prach AT, MacDonald TA, Hopwood DA, Johnston DA (1997) Increasing incidence of Barrett’s oesophagus: education, enthusiasm, or epidemiology? The Lancet 350(9082):933

[55] Qi Y, Liang J, She ZG, Cai Y, Wang J, Lei T, Stallcup WB, Fu M (2010) MCP-induced protein 1 suppresses TNFα-induced VCAM-1 expression in human endothelial cells[J]. FEBS Lett 584(14):3065–3072

[56] Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, Van Dongen S, Grocock RJ, Das PP, Miska EA (2007) Requirement of bic/microRNA-155 for normal immune function. Science 316(5824):608–611

[57] Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z (2012) Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. The Lancet. 379(9826):1591–1601

[58] Roy A, Zhang M, Saad Y, Kolattukudy PE (2013) Antidicer RNAse activity of monocyte chemotactic protein-induced protein-1 is critical for inducing angiogenesis. Am J Physiol Cell Physiol 305(10):C1021–C1032

[59] Singhal S, Stadanlick J, Annunziata MJ, Rao AS, Bhojnagarwala PS, O’Brien S, Moon EK, Cantu E, Danet-Desnoyers G, Ra HJ (2019) Human tumor-associated monocytes/macrophages and their regulation of Tcell responses in early-stage lung cancer. Sci Transl Med 11(479):eaat1500

[60] Skalniak L, Mizgalska D, Zarebski A, Wyrzykowska P, Koj A, Jura J (2009) Regulatory feedback loop between NF-κB and MCP-1-induced protein 1 RNase. FEBS J 276(20):5892–5905

[61] Skalniak L, Koj A, Jura J (2013) Proteasome inhibitor MG-132 induces MCPIP 1 expression. FEBS J 280(11):2665–2674

[62] Sønder SU, Saret S, Tang W, Sturdevant DE, Porcella SF, Siebenlist U (2011) IL-17-induced NF-κB activation via CIKS/Act1 physiologic significance and signaling mechanisms. J Biol Chem 286(15):12881–12890

[63] Stoeltzing O, Meric-Bernstam F, Ellis LM (2006) Intracellular signaling in tumor and endothelial cells: the expected and yet again, the unexpected. Cancer Cell 10(2):89–91

[64] Suzuki HI, Arase M, Matsuyama H, Choi YL, Ueno T, Mano H, Sugimoto K, Miyazono K (2011) MCPIP1 ribonuclease antagonizes dicer and terminates microRNA biogenesis through precursor microRNA degradation. Mol Cell 44(3):424–436

[65] Takeuchi O (2018) Endonuclease regnase-1/monocyte chemotactic protein-1-induced protein-1 (MCPIP1) in controlling immune responses and beyond. Wiley Interdiscip Rev RNA 9(1):e1449

[66] Uehata T, Iwasaki H, Vandenbon A, Matsushita K, Hernandez-Cuellar E, Kuniyoshi K, Satoh T, Mino T, Suzuki Y, Standley DM (2013) Malt1-induced cleavage of regnase-1 in CD4+ helper T cells regulates immune activation. Cell 153(5):1036–1049

[67] Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, Dinarello CA, Apte RN (2003) IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci 100 (5):2645–2650

[68] Wynn TA, Chawla A, Pollard JW (2013) Macrophage biology in development, homeostasis and disease. Nature 496(7446):445–455

[69] Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J, Henderson JM, Kutok JL, Rajewsky K (2008) Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 9(4):405–414

[70] Xu J, Peng W, Sun Y, Wang X, Xu Y, Li X, Gao G, Rao Z (2012a) Structural study of MCPIP1 N-terminal conserved domain reveals a PIN-like RNase. Nucleic Acids Res 40(14):6957–6965

[71] Xu J, Fu S, Peng W, Rao Z (2012b) MCP-1-induced protein-1, an immune regulator. Protein Cell 3(12):903–910

[72] Xu R, Li Y, Yan H, Zhang E, Huang X, Chen Q, Chen J, Qu J, Liu Y, He J (2019) CCL2 promotes macrophages-associated chemoresistance via MCPIP1 dual catalytic activities in multiple myeloma. Cell Death Dis 10(10):1–7

[73] Yao H, Ma R, Yang L, Hu G, Chen X, Duan M, Kook Y, Niu F, Liao K, Fu M (2014) MiR-9 promotes microglial activation by targeting MCPIP1. Nat Commun 5(1):1–2

[74] Zheng Y, Yang J, Qian J, Qiu P, Hanabuchi S, Lu Y, Wang Z, Liu Z, Li H, He J (2013) PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia 27(3):702–710

[75] Zhou L, Azfer A, Niu J, Graham S, Choudhury M, Adamski FM, Younce C, Binkley PF, Kolattukudy PE (2006) Monocyte chemoattractant protein-1 induces a novel transcription factor that causes cardiac myocyte apoptosis and ventricular dysfunction. Circ Res 98(9):1177–1185

RIGHTS & PERMISSIONS

2020 The Author(s) 2020